|Bid||20.00 x 1000|
|Ask||34.00 x 800|
|Day's range||30.18 - 31.86|
|52-week range||17.72 - 37.89|
|Beta (5Y monthly)||0.15|
|PE ratio (TTM)||101.27|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||36.86|
BioDelivery Sciences International (BDSI) raises its financial guidance for full-year 2021. BDSI expects sales at the high end of its previous guidance.
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
How far off is AnaptysBio, Inc. ( NASDAQ:ANAB ) from its intrinsic value? Using the most recent financial data, we'll...